a phase i/ii study of a 72-h continuous infusion of etoposide in advanced soft tissue sarcoma
Clicks: 208
ID: 185123
1997
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
208 views
22 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #24 of 68 articles by views in the journal of physiology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Purpose. The study was performed to assess the antitumour activity and toxicity of a 72-h continuous infusion of
single-agent etoposide as second-line treatment for patients with locally advanced or metastatic soft tissue sarcoma (STS),
following reports of substantial activity using this schedule of etoposide administration as first-line treatment in
combination with ifosfamide.
| Reference Key |
crawley1997sarcomaa
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Charles R. Crawley;Ian R. Judson;Mark Verrill;Catherine Hill;Florence I. Raynaud |
| Journal | the journal of physiology |
| Year | 1997 |
| DOI |
10.1080/13577149778236
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.